ALN-SOD vs Tofersen
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Amyotrophic Lateral Sclerosis
Shared mechanism: SOD1 · full Amyotrophic Lateral Sclerosis pipeline
ALN-SOD
Developed by Regeneron Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2032 · NCT06351592 (registry estimate)
No aligned efficacy figure on record for this race.
Tofersen · Qalsody
Marketed by Biogen and partners
NCT02623699 · Phase 3 · completed
The trial was randomized, quadruple-blind, and placebo-controlled, with 176 participants overall and 108 in the pivotal part. The hard clinical primary endpoint, change in ALSFRS-R score at Week 28, was not statistically significant: the least-squares mean change was -7.0 with tofersen versus -8.1 with placebo, with a treatment difference of 1.2 (95% CI -3.19 to 5.53; p=0.9689), so the result supports moderate rather than strong evidence.
Next expected readout: January 2027 · NCT07294144 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Amyotrophic Lateral Sclerosis
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
ALN-SOD: no structured comparison results are available for Amyotrophic Lateral Sclerosis.
Tofersen: registry results are on file for Amyotrophic Lateral Sclerosis, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALN-SOD's landscape · Tofersen's landscape